Glycerol
metaboliteGlycerol elevation reflects acute lipid mobilization and ischemia-driven metabolic perturbation in ACS.
Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencemedium
RationaleLipid-breakdown product elevated in ACS; marker of systemic lipolysis and ischemic metabolic stress.
Also acts inLipid entry/oxidation
Druggability
Not assessed (no mapped human gene target).
Type I vs non-Type I discrimination
ScoresNon-Type-I-associated
R — rupture / Type-I—
C — non-Type-I50
A — assay feasibility42
E — evidence strength35
T1DI (composite)5
Specificity differential (R−C)-35
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationn/a
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmian/a
2hypoxemia / respiratory failuren/a
2hypertensive emergencyn/a
2high-demand / peri-operative stressmag 1
3sudden cardiac deathn/a
4aPCI-related periproceduraln/a
4bstent thrombosisn/a
4cin-stent restenosisn/a
5CABG-relatedmag 2
Coverage: 2/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 4 supporting references. See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research
Literature evidence(1)
- GC-MS validation and analysis of targeted plasma metabolites related to carbonyl stress in type 2 diabetes mellitus patients with and without acute coronary syndrome.Biomedical chromatography : BMC · 2024 · PMID 38966927 · doi